News

Eugene Wright, Jr., MD, joins the show to discuss the current state of technological integration into diabetes care, from glucose monitors to insulin delivery and beyond.

Buse discusses phase VESPER results, berobenatide's weight loss potential, and expectations for the upcoming phase 3 program

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has demonstrated its efficacy in reducing several major factors of obesity versus placebo.

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has outperformed placebo in patients with poorly-controlled T2D.

The CONNECT trial found CGM improved A1C and time in range in adults with type 2 diabetes not on insulin.

VESPER-1 and VESPER-3 findings highlight the potential of berobenatide, an investigational ultra-long-acting GLP-1 RA, for overweight or obesity with or without type 2 diabetes.

A post-hoc analysis of the STEP UP trial found that semaglutide 7.2 mg and 2.4 mg were linked to eGFR increases in adults with obesity who did not have diabetes.

STEP UP T2D data suggest semaglutide 7.2 mg's superiority to the 2.4 mg dose and placebo for proposed BMI and waist-to-height ratio treatment targets.

An EHR-based machine learning model predicted 10-year type 2 diabetes risk with near-ideal calibration in over 3 million adult patients.

Alexis Marcotte-Chénard, PhD, discusses his presentation on “exercise snacks” and how they can lower blood pressure and improve HbA1c in sedentary patients.

From hepatitis D's first FDA-approved therapy to advances in hepatitis B and PBC, May delivered major developments in hepatology.

From FDA-approved at-home TMS and accelerated protocols to conversational AI matching group therapy outcomes, here are 5 psychiatry updates from May every clinician should know.

ACCESS phase 2b data show aleniglipron 120 mg produced 11.3% placebo-adjusted weight loss at 36 weeks, with continued reductions in the OLE.

Vleugels discusses Part B findings on investigational IL-13 inhibitor zumilokibart (APG777) in adult patients with moderate-to-severe atopic dermatitis.

Sood discusses emerging diabetes technologies, from automated insulin delivery to dual glucose-ketone monitoring, at ADA 2026.

Teplizumab, which has recently seen a substantial label expansion into pediatric patients, is matching its safety and efficacy data in the clinic.

From a one-time CRISPR therapy cutting HAE attacks by 87% to CSU biomarkers and emerging ILIT research, here are the 5 allergy stories worth catching up on from May 2026.

In the final segment, the clinicians evaluate the guideline's nuanced positioning of phototherapy relative to newer systemic agents and highlight a gap.

Krakowski and Torres-Zegarra discuss how to initiate the conversation about systemic therapy with families and review the guideline's drug hierarchy.

The experts review the guideline's approach to topicals for active atopic dermatitis, covering the appropriate use of topical corticosteroids and more.

This segment examines how the guideline navigates the tension between GRADE-based evidence thresholds and long-established clinical practices.

This discussion highlights disease prevention and the foundational role of moisturization, with the experts examining emollient use.

Pediatric dermatologists introduce the first pediatric-specific evidence-based guidelines for atopic dermatitis and discuss.

Phase 3 TETON-1 data show inhaled treprostinil reduced FVC decline by 130 mL and cut clinical worsening risk 33% in IPF patients over 52 weeks, according to Steven Nathan, MD.

5 interviews. 5 minutes. The asthma data from ATS 2026 your patients will be asking about.

This Q&A interview highlights findings on the lifelong impacts on education and career faced by some patients with childhood diagnoses of atopic dermatitis.

Hear Jim Januzzi, MD, discuss how he overcame academic shortcomings to become one of the preeminent voices in cardiology biomarkers.

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.